CORDIS
EU research results

CORDIS

English EN

The European malaria vaccine development association

Objective

The goal of the European Malaria Vaccine Development Association (EMVDA) integrated project is to systematically develop and test prototype malaria vaccines by comparative and continuous evaluation of candidate vaccines and move these as quickly as possible to clinical studies. Our emphasis will be on 'downstream' vaccine pre- clinical development and clinical trials. A product development management structure will be set up that will be responsible for the technical and regulatory management of the transition of candidate vaccines between the production groups and clinical testing groups. Exploiting the capabilities of 3 SMEs, 9 European malaria vaccine research centres, the European Malaria Vaccine Initiative (EMVI) and the African Malaria Network (AMANET), we aim to establish a scientific and technological structure supported by effective management. Stringent go/no-go criteria will be used to assess and compare competing antigens and delivery systems to focus resources on to the most credible vaccine candidates. Our internal Training Programme, which will be integrated with that of the existing Framework Programme 6 funded malaria-oriented Network of Excellence (BIOMALPAR) will promote interdisciplinary collaboration and support for our African partners, AMANET, particularly with their training programmes for young African scientists. Working closely with our African partners, standard operating procedures governing all in vitro and in vivo immuno-assays used by the consortium during vaccine development will be developed and distributed. The EMVDA project brings together Europe's leading malaria vaccine researchers and pan-Union initiatives in an unprecedented collaboration with vaccine SMEs and the African Malaria Network to drive the production and clinical development of an effective vaccine to protect those vulnerable to this disease and thus aid human development.'

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EUROPEAN VACCINE INITIATIVE

Address

Im Neuenheimer Feld 307
Heidelberg

Germany

Participants (15)

Sort alphabetically

Expand all

CRUCELL HOLLAND B.V.

Netherlands

PEVION BIOTECH LTD.

Switzerland

CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE

Netherlands

THE UNIVERSITY OF EDINBURGH

United Kingdom

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

MEDICAL RESEARCH COUNCIL

United Kingdom

AFRICAN MALARIA NETWORK TRUST

Tanzania

SWISS TROPICAL INSTITUTE

Switzerland

STOCKHOLM UNIVERSITY

Sweden

HOSPICES CANTONAUX CHUV

Switzerland

EBERHARD-KARLS UNIVERSITAET TUEBINGEN

Germany

ETNA BIOTECH S.R.L.

Italy

RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Germany

STATENS SERUM INSTITUT

Denmark

Project information

Grant agreement ID: 37506

  • Start date

    1 December 2006

  • End date

    31 May 2012

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 15 887 654

  • EU contribution

    € 13 500 000

Coordinated by:

EUROPEAN VACCINE INITIATIVE

Germany